Prime Medicine (PRME) Stock
Gene editing company developing treatments for genetic disorders. Here's the price, business snapshot, and what's worth knowing about Prime Medicine in August 2026.
Prime Medicine, Inc. (PRME) is a clinical-stage biotechnology company focused on in vivo gene correction therapies using next-generation gene editing platforms. The company aims to develop precise molecular tools designed to repair disease-causing mutations directly in patients’ cells, targeting a range of rare and more common genetic disorders. With a market capitalisation near $977 million, Prime is still early in its clinical and preclinical development, so value is closely tied to trial results, regulatory milestones and partnerships. Investing in Prime means weighing potential for meaningful therapeutic breakthroughs against typical biotech risks: clinical failure, long timelines, funding needs and regulatory uncertainty. The company’s science may offer differentiated approaches, but translating lab success into safe, effective, and reimbursable treatments is challenging. This information is general and educational, not personal advice — investors should consider their own risk tolerance, do further research and, if needed, consult a financial adviser. Past performance is not a guide to future returns; values can rise and fall.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Prime Medicine’s stock, anticipating it could rise significantly in value.
Financial Health
Prime Medicine Inc is generating modest revenue and cash flow, but its financial standing needs improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Early-stage upside
Clinical milestones can change valuation quickly, though trial setbacks are common; watch data releases and regulatory signals.
Technology edge
Proprietary editing platforms aim for precise in vivo correction — scientifically promising but dependent on successful translation to patients.
Market potential
If therapies prove safe and effective, they could address rare and prevalent conditions, yet commercialisation and reimbursement remain uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
